[go: up one dir, main page]

PT3495352T - Formas de cristal de um antagonista de recetor de androgénio, método de preparação e utilização das mesmas - Google Patents

Formas de cristal de um antagonista de recetor de androgénio, método de preparação e utilização das mesmas

Info

Publication number
PT3495352T
PT3495352T PT178429809T PT17842980T PT3495352T PT 3495352 T PT3495352 T PT 3495352T PT 178429809 T PT178429809 T PT 178429809T PT 17842980 T PT17842980 T PT 17842980T PT 3495352 T PT3495352 T PT 3495352T
Authority
PT
Portugal
Prior art keywords
preparation
receptor antagonist
crystal form
method therefor
androgen receptor
Prior art date
Application number
PT178429809T
Other languages
English (en)
Original Assignee
Crystal Pharmaceutical Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmaceutical Suzhou Co Ltd filed Critical Crystal Pharmaceutical Suzhou Co Ltd
Publication of PT3495352T publication Critical patent/PT3495352T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT178429809T 2016-08-26 2017-08-25 Formas de cristal de um antagonista de recetor de androgénio, método de preparação e utilização das mesmas PT3495352T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610737732 2016-08-26
CN201610871736 2016-09-30
CN201610876685 2016-10-08

Publications (1)

Publication Number Publication Date
PT3495352T true PT3495352T (pt) 2021-05-03

Family

ID=61246439

Family Applications (1)

Application Number Title Priority Date Filing Date
PT178429809T PT3495352T (pt) 2016-08-26 2017-08-25 Formas de cristal de um antagonista de recetor de androgénio, método de preparação e utilização das mesmas

Country Status (16)

Country Link
US (1) US10815221B2 (pt)
EP (1) EP3495352B1 (pt)
JP (1) JP6716023B2 (pt)
CN (1) CN109641851B (pt)
CY (1) CY1124083T1 (pt)
DK (1) DK3495352T3 (pt)
ES (1) ES2869882T3 (pt)
HR (1) HRP20210667T1 (pt)
HU (1) HUE053958T2 (pt)
LT (1) LT3495352T (pt)
PL (1) PL3495352T3 (pt)
PT (1) PT3495352T (pt)
RS (1) RS61773B1 (pt)
SI (1) SI3495352T1 (pt)
SM (1) SMT202100251T1 (pt)
WO (1) WO2018036558A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018162793A1 (en) * 2017-03-07 2018-09-13 Orion Corporation Manufacture of a crystalline pharmaceutical product
WO2019028689A1 (zh) * 2017-08-09 2019-02-14 杭州领业医药科技有限公司 Odm-201晶型及其制备方法和药物组合物
EP3759076A1 (en) * 2018-02-27 2021-01-06 Sandoz AG Crystalline form ii of darolutamide
US20200253877A1 (en) * 2018-10-18 2020-08-13 Neurobo Pharmaceuticals, Inc. Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
WO2022036782A1 (zh) * 2020-08-18 2022-02-24 拜耳消费者护理股份有限公司 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途
MX2024009980A (es) 2022-02-28 2024-08-26 Quim Sintetica S A Forma cristalina de darolutamida.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
EA024245B1 (ru) * 2011-04-21 2016-08-31 Орион Корпорейшн Карбоксамиды, модулирующие андрогенные рецепторы
EP3250554B1 (en) * 2015-01-30 2022-05-18 Orion Corporation A carboxamide derivative and its diastereomers in stable crystalline form
WO2019028689A1 (zh) * 2017-08-09 2019-02-14 杭州领业医药科技有限公司 Odm-201晶型及其制备方法和药物组合物

Also Published As

Publication number Publication date
JP6716023B2 (ja) 2020-07-01
DK3495352T3 (da) 2021-05-03
US20200239450A1 (en) 2020-07-30
EP3495352A1 (en) 2019-06-12
ES2869882T3 (es) 2021-10-26
LT3495352T (lt) 2021-06-10
WO2018036558A1 (zh) 2018-03-01
SI3495352T1 (sl) 2021-08-31
HRP20210667T1 (hr) 2021-05-28
PL3495352T3 (pl) 2021-08-02
JP2019526570A (ja) 2019-09-19
EP3495352A4 (en) 2019-06-12
EP3495352B1 (en) 2021-01-27
US10815221B2 (en) 2020-10-27
SMT202100251T1 (it) 2021-05-07
CY1124083T1 (el) 2022-03-24
CN109641851A (zh) 2019-04-16
HUE053958T2 (hu) 2021-08-30
RS61773B1 (sr) 2021-05-31
CN109641851B (zh) 2022-09-02

Similar Documents

Publication Publication Date Title
IL252055A0 (en) Blood brain barrier receptor antibodies and methods of use
PT3495352T (pt) Formas de cristal de um antagonista de recetor de androgénio, método de preparação e utilização das mesmas
IL252172A0 (en) Expandable drug delivery devices and methods of use
HK1250710A1 (zh) 用於製備雄激素受體拮抗劑及其中間體的方法
HK1256860A1 (zh) 喹唑啉衍生物的晶體及其製備方法
HK1245794A1 (zh) 咪唑並噁嗪晶體、含有所述晶體的藥物組合物和製備所述晶體的方法
SG11201609948YA (en) Lobaplatin crystal, preparation method and pharmaceutical application
IL248578A0 (en) Quinzoline derivatives, pharmaceutical compounds containing them and their uses
HK1252375A1 (zh) 喹唑啉衍生物的晶體及其製備方法
PT3539545T (pt) Forma cristalina de antagonista do recetor de gnrh e método para a preparação da mesma
PT3216791T (pt) Substância polimórfica de cloridrato de yonkenafil, método de preparação e composição e uso da mesma
HK1253294A1 (zh) 阿片受體調節劑及其用途
HK1250163A1 (zh) 作為5-氧代-ete受體拮抗劑的吲哚類似物及其使用方法
IL254597A0 (en) Crystalline form of ahu377, method for its preparation and use
EP3336088A4 (en) CRYSTALLINE FORM OF THE OREXIN RECEPTOR ANTAGONIST COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF
HUE050459T2 (hu) Androgénreceptor-gátló kristályformája és annak elõállítási eljárása
HK1210773A1 (en) Crystal form of dabigatran etexilate mesylate and preparation method and use thereof
PT3303297T (pt) Novo método para a preparação de base de ivabradina de elevada pureza e sais da mesma